Sangamo Therapeutics Inc (LTS:0R1D)
$ 0.51 -0.063 (-10.99%) Market Cap: 103.78 Mil Enterprise Value: 80.18 Mil PE Ratio: 0 PB Ratio: 1.80 GF Score: 33/100

Sangamo Therapeutics Inc at JPMorgan Healthcare Conference Transcript

Jan 16, 2020 / 04:30PM GMT
Release Date Price: $8.56
Eric William Joseph
JP Morgan Chase & Co, Research Division - VP & Senior Analyst

Good morning. I'm Eric Joseph, senior biotech analyst here at JPMorgan. And our next presenting company is Sangamo Therapeutics. I'm pleased to welcome CEO, Sandy Macrae, to tell us a little bit about the company. Following the presentation, the breakout Q&A will be across the hall in the Georgian room. With that, Sandy?

Alexander D. Macrae
Sangamo Therapeutics, Inc. - CEO, President & Director

Thanks, Eric. Good morning. I'm Sandy. I have the privilege to lead Sangamo. I would refer you, of course, to our forward-looking statement. And I want to give a talk today that is about balance and about responsibility. We had an R&D day just last month, and there's some excellent presentations there that will give you the full detail on the programs. So I want to give an overview of how we think about Sangamo and the balance and responsibility that we have.

And we have a responsibility to patients, of course. We have a responsibility to you all to make

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot